Tradestie Institutional Equity Comparison Engine

HHS vs CRESY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRESY Overall Edge

CRESY Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cresud SA (CRESY) driven by superior Growth & Margin, Options & Structure while HHS counters with relative strength in Valuation, Momentum & Technical. Fundamentally, HHS trades at 14.3x Forward P/E with -3.2% operating margin (-1.7% YoY revenue) versus CRESY at 56.6x Forward P/E and 19.3% operating margin (+20.4% YoY). In options structure, HHS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CRESY sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HHS
HHS 14.3x vs CRESY 56.6x Fwd P/E
Growth & Margin Winner CRESY
Op Margin -3.2% vs 19.3% ยท YoY -1.7% vs +20.4%
Momentum & Technical Winner HHS
1Y +9.1% vs -20.3% ยท 52W Pos 69% vs 8%
Options & Structure Winner CRESY
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (100th %ile IV)
HHS US Equity
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.85
-3.99% 1D
Market Cap $29.9M
1M Return -10.26%
1Y Return +9.07%
Forward P/E 14.3x
Unified AI Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
CRESY NASDAQ
Cresud SA
Real Estate
$9.17
-5.85% 1D
Market Cap $690.8M
1M Return -20.4%
1Y Return -20.26%
Forward P/E 56.6x
Unified AI Score
54.6 / 100 HOLD
Tech 75.0 Fund 55.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HHS +9.07% CRESY -20.26% Spread: +55.35 pp (HHS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
HHS TTM Op. Margin: -3.2% CRESY TTM Op. Margin: 19.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HHS vs CRESY. Trailing 12-month operating profitability (HHS -3.2% vs CRESY 19.3%) and valuation multiples (HHS 14.3x vs CRESY 56.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HHS (4) vs CRESY (6)
Institutional Metric HHS CRESY Criterion Row Winner
Market Capitalization Scale $29.9M $690.8M Larger Scale CRESY
Trailing P/E Ratio Valuation 14.3x 6.3x Lower Multiple CRESY
Forward P/E Ratio Valuation 14.3x 56.6x Lower Multiple HHS
Revenue Growth (YoY) Growth -1.7% +20.4% Higher Growth CRESY
Operating Margin (TTM) Profitability -3.2% 19.3% Higher Margin CRESY
Net Profit Margin Profitability -3.7% 9.6% Higher Margin CRESY
Return on Equity (ROE) Capital Efficiency -30.4% 8.6% Higher ROE CRESY
52-Week Range Position Momentum 69% ($2โ€“$5) 8% ($9โ€“$14) Stronger Trend HHS
Beta / 30D Volatility Risk Regime 0.49ฮฒ ยท 46% Vol 0.82ฮฒ ยท 59% Vol Lower Realized Risk HHS
Unified Institutional Score Composite Signal 61.8 / 100 (BUY) 54.6 / 100 (HOLD) Higher Composite HHS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HHS vs CRESY Buy Guide
HHS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live HHS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CRESY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live CRESY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HHS nor CRESY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.